



USAID
FROM THE AMERICAN PEOPLE

TB CARE I

TB CARE I - Kenya

**Year 2
Quarterly Report
January-March 2012**

April 30, 2012

Quarterly Overview

Reporting Country	Kenya
Lead Partner	KNCV
Collaborating Partners	MSH, ATS
Date Report Sent	{27/04/2012}
From	Dr. Valentina Anisimova, TB CARE I Country Director
To	Dr. Maurice Maina, USAID Country Mission
Reporting Period	January-March 2012

Technical Areas	% Completion
1. Universal and Early Access	29%
2. Laboratories	32%
3. Infection Control	30%
4. PMDT	6%
5. TB/HIV	0%
6. Health Systems Strengthening	25%
7. M&E, OR and Surveillance	8%
8. Drug supply and management	36%
Overall work plan completion	21%

Most Significant Achievements

Implementation of Gene Xpert Machines in Kenya

TB CARE I Kenya has been supporting the Division of Leprosy TB and lung Diseases to improve tuberculosis (TB) case detection, including smear-negative disease often associated with HIV as well as expanded capacity to diagnose multidrug-resistant tuberculosis (MDR-TB). In 2011, TB CARE I Kenya procured 3 Gene Xpert machines, 3 computers, 3 UPSs and 1000 cartridges. The machines and accessories were handed over to the Division of Leprosy TB and Lung diseases (DLTLD) in September 2011. **These were the first Gene Xpert machines in the public sector** and they were installed in Coast provincial General Hospital (Coast PGH), Port Reitz District Hospital and Likoni District Hospital all within the Coast region. The laboratory personnel were trained and clinicians in the region sensitized to fully utilize the machines. A follow up support supervision visit was made in March 2012. There was good progress so far in the use of the Gene Xpert machines although there is need to sensitize more clinicians in the region.

The algorithm for Gene Xpert testing was developed with TB CARE I support. It targets re-treatment cases, health care workers at risk, MDR TB patient's contacts, HIV positive smear negatives, children under 5 and sputum smear positive refugees. From October 2011 to February 2012, a total of 531 samples have been tested. Out of these, 223 cases were MTB positive. 39 of these were new TB cases and 10 were Rifampicin (Rif) resistant. It is notable that all the 10 Rif cases were previously treated TB cases. All the 10 Rif resistant cases were put on standardised second line TB treatment. Six of the ten were confirmed MDR TB cases by HAIN MTBDRplus, out of the 6, 2 have been confirmed by MGIT960 DST while confirmation for the rest is ongoing.

Strengthening AFB microscopy through procurement of LED microscopes

Laboratory capacity is a critical component of a successful TB control program. The AFB microscopy is still the main TB diagnostic and treatment monitoring method. The TB CARE I is supporting the Division of TB, Leprosy and other Lung Diseases (DLTLD) to provide quality accessible laboratory services in the country. In order to achieve these, TB CARE I procured 17 LED microscopes to be distributed to high volume TB diagnostic facilities countrywide in addition to the previous 20 making a total of 37. These type of microscopes reduces the turn-around time and increases sensitivity for TB diagnosis. The handing over of the 17 microscopes to the DLTLD was done on 31st January 2012.

Overall work plan implementation status

TB CARE I APA 2 project in Kenya is being implemented for 11 months (November 2011 to September 2012). The implementation process has started well and it is expected that the objectives of the project will be met within the project duration. The overall work implementation stands at about 21%. Activities contributed to the achievement include universal and early access, support of TB laboratories, health systems strengthening through supervision and supply and management of drugs. On the fact that . Subagreement with the local implementing partners (KAPTLD & KANCO) will be finalized. Other major activities that are planned to start in the next quarter include support to MDR TB patients, EQA and printing of data tools ; technical assistance to support national electronic surveillance system ; as well as continue support supervision.

Technical and administrative challenges

Some of the major activities had not kicked off by the end of the quarter due to late approval of APA 2 budget. For example the Scale up of patient charter implementation has not started because the subagreement between TB CARE I and the local implementing partners has not been done. The TB CARE I Country Director for Kenya (Dr. Sentayehu Tsegaye) resigned and left at the end of March 2012. In the interim period (as a new Director is being recruited) TB CARE I country office has contracted Dr. Valentina Anisimova as the Interim Country Director to ensure that TB CARE I activities continue to be implemented as planned. This plan has been shared with all the partners including the USAID country mission.

In-country Global Fund status and update

Global Fund Tuberculosis Grant for Kenya is a Single Stream of Funding (SSF), Grant number:KEN-S11-G11-T. The Principal Recipient of the grant in Kenya is African Medical and Research Foundation (AMREF). The grant duration is from 01 January 2011 to 30 June 2013 and currently phase I of the grant is in progress. The total signed amount for phase I is USD 6,017,973 and the last disbursed amount of USD 3,523,304 was disbursed on 23 November 2011. The latest performance rating is A2 as of 20 February 2012.

Quarterly Technical Outcome Report

Technical Area 1. Universal and Early Access								
Expected Outcomes	Outcome Indicators	Baseline		Target		Result Y1	Highlights of the Quarter	Challenges and Next Steps to Reach the Target
		Data	Year	Data	Year			
1.1 Increased demand for and use of high quality TB services and improve the satisfaction with the services provided (Population/Patient Centered Approach)	1.1.3 Patients' Charter is implemented Indicator Value: Score (0-3) based on definition	2	2011	3	2012		Activity not done. There was a delay in signing the subagreement with the local partner implementing this activity (KANCO)	CSO (KANCO) is expected to assess the use of patient charter and ISTC within its operational regions. The sub agreement contract between KNCV and KANCO not yet in place. Revision of the budget for KANCO is in progress. The sub-agreement is expected to be signed before end of April 2012.
	1.1.4 Gender and poverty policy document developed Description: Indicator Value:Yes/No Level: National Source: Activity report	N	2011	Y	2012		Draft Poverty & Gender Guidelines developed. Finalization of the guidelines on going. Stakeholders' workshop planned in June 2012	Workshop for stakeholders to provide input to the draft guidelines
	1.1.5 Increased TB case finding in the target districts Description: Indicator Value:Percent	TBD	2011	15%	2012		To be implemented after the Poverty & Gender Guidelines are in place	Awaiting the finalization of TB Poverty & Gender Guidelines
1.2 Increased quality of TB services delivered by all care providers (Supply)	1.2.1. Appropriate tools from the PPM Toolkit is implemented Indicator Value: Score (0-3) based definition disaggregated by the tools selected by NTP-National Situational Analysis	1	2011	2	2012		7 out of the 14 PPM tools being implemented. These include: Advocacy & Communication M&E ISTC Private practitioners Workplaces TB/HIV Collaboration PMDT	
	1.2.5 Proportion of TB cases (all forms) notified by Non-public providers in project sites Description: TB cases notified by private health facilities, work place and other non-public facilities Indicator Value:Percent Level: District Source:Activity report Means of Verification:Supportive supervision Numerator: number of TB Cases notified in non public providers in project districts Denominator:number of total cases notified by the project districts	TBD	2011	TBD	2012		Data for Oct- Dec 2012 to be provided next quarter	

Technical Area	2. Laboratories					Result Y1	Highlights of the Quarter	Challenges and Next Steps to Reach the Target	
	Expected Outcomes	Outcome Indicators	Baseline		Target				
			Data	Year	Data				Year
2.1 Ensured capacity, availability and quality of laboratory testing to support the diagnosis and monitoring of TB patients	2.1.2 Laboratories with working internal and external quality assurance programs for tests that they provide including: a) smear microscopy, b) culture, c) DST, and d) rapid molecular test Indicator Value: Percent Numerator: Number of laboratories enrolled in EQA program meeting description above both nationwide and TB CARE areas.(Maintain EQA coverage of APA 1 =1239 labs) Denominator: All laboratories (national and TB CARE areas separately) that perform one or more of the above TB diagnostics = 1549 labs	80 (1239/1549)	2011	80	2012		Data for EQA: EQA coverage for Oct-Dec 2011 is 72% Total number of slides rechecked: 10,541 913 out of 1265 laboratories from 9 TB regions participated in EQA. Data from 3 regions missing. Error rates: (HFP + HFN) is 4%	Delay in submission of reports from the field is associated with the APA 2 budget approval.	
	2.1.5 proportion of retreatment specimens submitted for culture/DST Description: percentage of retreatment sputum samples submitted to central reference laboratory for culture/DST Indicator Value:Percent Level: National Source: activity report Means of Verification: Numerator: Number of retreatment specimens submitted=about 75000 Denominator: Number of total retreatment cases notified=about 10,000	70 (7500/10000)	2011	75	2011		A total of retreatment specimens received in CRL (October 2011-786, November 2011-901, December 2011-675, January 2012 - 618, February 2012- 540, March 2012-634) Proportion of retreatment cases currently can not be estimated due to technical challenges at CRL.	Continue to support DR TB surveillance	
2.3 Ensured optimal use of new approaches for laboratory confirmation of TB and incorporation of these approaches in national strategic laboratory plans	2.3.1 New technologies have been introduced Indicator Value: Number for each technique below by Central, Provincial, district and Peripheral levels 1. TB culture 2. First line DST 3. Second-line DST 4. HAIN MTBDRplus 5. GeneXpert 6. LED microscopy	1 (GeneXpert)	2011	1	2012		Gene Xpert data from Oct 2011 to Feb 2012 for the 3 Gene Xpert machines at the Coast region. The algorithm targets retreatment cases, health care workers at risk, MDR TB patients contacts, HIV +ve & smear -ve, children under 5 and refugees SSM+. A total of 531 samples have been tested: -223 cases were MTB positive -39 were new TB cases -10 cases were Rif resistant (on 2nd line TB treatment)	Challenges: 1. Low work load and risk of expiration of cartridges. 2. No samples from children under five tested yet Next Steps: 1. Expand sensitization of neighbouring districts/regions on the use of Gene Xpert 2. Introduction of sputum induction and gastric lavage collection in Coast PGH and Portreitz hospitals (APA 3). 3.Continue to monitor the implementation of Gene Xpert	

	2.3.2 Laboratories offering rapid tests for TB or drug-resistant TB Indicator Value: Number of laboratories Numerator: Number of laboratories using GeneXpert MTB/RIF and HAIN MTBDRplus disaggregated by type of technology and also disaggregated by national and TB CARE areas.	3 (GeneXpert)	2011	3	2012		1 laboratory using HAIN MTBDRplus (CRL) 3 laboratories using Gene Xpert (Coast Region)	Continue to monitor and support the laboratories
	2.3.3 Rapid tests conducted Indicator Value: Number of tests Numerator: Annual number of tests (separately for GeneXpert MTB/RIF and HAIN MTBDRplus) conducted disaggregated by national and TB CARE areas.	0	2010	2000 (geneXpert)	2012		Total of 620 samples tested by Gene Xpert (October 2011 to March 2012) Jan to March 2012 : 311	Challenges: 1. Low work load and risk of expiration of cartridges. 2. No samples from children under five tested yet Next Steps: 1. Expand sensitization of neighbouring districts/regions on the use of Gene Xpert 2. Introduction of sputum induction and gastric lavage collection in Coast PGH and Portreitz hospitals (APA 3). 3. Continue to monitor the implementation of Gene Xpert

Technical Area 3. Infection Control

Expected Outcomes	Outcome Indicators	Baseline		Target		Result	Highlights of the Quarter	Challenges and Next Steps to Reach the Target
		Data	Year	Data	Year	Y1		
3.1 Increased TB-IC Political Commitment	3.1.4 TBIC training material developed Description: IC training materials developed Indicator Value: Yes/No Level: National Source: Activity report	N	2011	Y	2012		Draft training materials developed and shared with stakeholders. Awaiting for feedback/inputs before finalization	Finalization workshop planned for July 2012

Technical Area 4. PMDT

Expected Outcomes	Outcome Indicators	Baseline		Target		Result	Highlights of the Quarter	Challenges and Next Steps to Reach the Target
		Data	Year	Data	Year	Y1		
4.1 Improved treatment success of MDR TB	4.1.5 MDR Patients getting patient support through TB CARE I Description: number of MDR patients getting patient support package through TB CARE I Indicator Value: number Level: National Source: Activity report Means of Verification: Finance report	160	2011	210	2012		MDR Patient support currently provided by GF. To be continued from May 2012. MDR TB contact tracing done. 17 contacts of MDR TB patients traced and screened for TB A total of 21 MDR TB cases confirmed (Jan-March).	Increase contact tracing for MDR TB patients. Due to technical challenges at the CRL, linkage information between contacts and confirmed casts is currently not available but will be reported next quarter.

Technical Area 5. TB/HIV								
Expected Outcomes	Outcome Indicators	Baseline		Target		Result	Highlights of the Quarter	Challenges and Next Steps to Reach the Target
		Data	Year	Data	Year	Y1		
5.2 Improved diagnosis of TB/HIV co-infection	5.2.5 TB/HIV sites with IPT tools Description: Number of TB/HIV sites with updated IPT tools Indicator Value: Number Level: National Source: Activity report Means of Verification: Supportive supervision Numerator: Number of TB/HIV sites with updated IPT tools	TBD	2011	220	2012		Draft IPT tools in place. Finalization of the IPT tool to be done in May 2012	

Technical Area 6. Health Systems Strengthening								
Expected Outcomes	Outcome Indicators	Baseline		Target		Result	Highlights of the Quarter	Challenges and Next Steps to Reach the Target
		Data	Year	Data	Year	Y1		
6.1 TB control is embedded as a priority within the national health strategies and plans, with matching domestic financing and supported by the engagement of partners	6.1.3 CCM and/or other coordinating mechanisms include TB civil society members and TB patient groups Indicator Value: Yes/No	Y	2011	Y	2012		No coordination mechanisms conducted during the reporting quarter	Challenges: -CCM meetings not held regularly -Stop TB Partnership meetings not held in the quarter Next Steps -Liase with DLTLD & Stop TB Partnership secretariate
	6.1.4 NTP ISO Certified Description: ISO certification Indicator Value: Yes/No Level: National Source: Activity report Means of Verification: Activity Delivery report	N	2011	Y	2012		ISO certification process on going. Stage I and II audit to be conducted by Kenya Bureau of Standards in May 2012.	Delay in activity associated APA 2 approval
	6.1.6 Use of new technology in TB program Management Description: Realtime reporting using mobile technology in place for program management Indicator Value: Yes/No Level: National Source: Activity report Means of Verification: Service Delivery report	N	2011	Y	2012		A new technology to support the development of web based reporting and management of the TB program in Kenya through Safaricom communication provider has been proposed. This is to be approved by PMU and USAID before it is implemented.	Approval of the Safaricom Sub agreement is pending
6.2 TB control components (drug supply and management, laboratories, community care, HRD and M&E) form an integral part of national plans, strategies and service	6.2.1 Supervisory visits conducted according to country supervisory standards Indicator Value: Percent Numerator: Number of annual supervisory visits conducted to DOTs sites=16,000 visits Denominator: Number of annual supervisory visits planned=21,500 visits.	78	2011	75	2012		Monthly districts supervision coverage: October 2011 - 76%, November 2011 - 74%, December 2011 - 64%, January 2012 - 81%	Data for February and March 2012 to be reported next quarter

Technical Area 7. M&E, OR and Surveillance		Baseline		Target		Result	Highlights of the Quarter	Challenges and Next Steps to Reach the Target
Expected Outcomes	Outcome Indicators	Data	Year	Data	Year	Y1		
7.1 Strengthened TB surveillance	7.1.1 An electronic recording and reporting system for routine surveillance exists at national and/or sub-national levels Indicator Value: Yes/No	Y	2011	Y	2012		Activity planned for next quarter	
	7.1.2 Diagnosed cases captured by routine surveillance system Indicator Value: Percent	TBD	2011	TBD	2012		Activity not done	Electronic reporting system not yet in place
7.2 Improved capacity of NTPs to analyze and use quality data for the management of the TB program	7.2.2 NTP provides regular feedback from central to lower levels Indicator Value: Percent per quarter Numerator: Number of quarterly feedback reports prepared and disseminated to provincial level (24 feedbacks during 24 review meeting sessions) Denominator: Total number of expected provincial level review meetings with district TB program coordinators in a year (48 review meetings)	unknown	2011	50%	2012		No supervision visits made by central level to provinces during the reporting quarter	

Technical Area 8. Drug supply and management		Baseline		Target		Result	Highlights of the Quarter	Challenges and Next Steps to Reach the Target
Expected Outcomes	Outcome Indicators	Data	Year	Data	Year	Y1		
8.1 Ensured nationwide systems for a sustainable supply of drugs	8.1.4 NTP request on TB commodity addressed Description: assistance on reducing clearance delay and emergency drug distribution Indicator Value: Number of requests addressed Level: National Source: Activity report Means of Verification: TB CARE I finance report	Unknown	2011	10	2012		Support provided to distribute drugs to three regions during reporting period: Rift Valley North, Nyanza South & Western Support provided for Clearance of drugs twice during the reporting quarter.	

Quarterly Activity Plan Report

1. Universal and Early Access								
Outcome	Activity #	Activity	Activity	Approved Budget	Cumulative Completion	Planned Completion Month	Year	Cumulative Progress and Deliverables up-to-date
1.1 Increased demand for and use of high quality TB services and improve the satisfaction with the services provided (Population/Patient Centered Approach)	1.1.1	Scale up Patients' charter implementation by enhancing patient engagement	KNCV	88,235	0%	Sept	2012	Activity not done. Awaiting sub agreement with implementing partner (KANCO)
	1.1.2	Pilot ICF using "TB Case Finding SOP"	MSH	16,682	30%	June	2012	Customization of the tools is on going to be completed in April 2012.
	1.1.3	Finalize Gender & Poverty Policy document	KNCV	5,882	30%	Mar	2012	Finalization process on going. Draft policy in place. Workshop planned in June 2012 to get further input from all stakeholders
	1.1.4	Pediatric Training material development	KNCV	10,623	30%	Sept	2012	Draft training materials developed. To be finalized by June 2012
Outcome	Activity #	Activity	Activity	Approved Budget	Cumulative Completion	Month	Year	Cumulative Progress and Deliverables up-to-date
1.2 Increased quality of TB services delivered by all care providers (Supply)	1.2.1	Adoption & implementation of appropriate tool from the PPM toolkit	KNCV	346,257	25%	Sept	2012	PPM tools being implemented include: Advocacy & Communication, M&E, ISTC, Private practitioners, Workplaces, TB/HIV Collaboration
	1.2.2	Improve quality and standardize TB diagnosis and treatment by all providers	KNCV	101,533	31%	Sept	2012	Continuous Medical Education session held in Kisumu for 50 lab personnel (M-32, F-18) Development of web based training program initiated 2 trainings on TB/HIV conducted for 47 HCWs (M-12, F-33) 3 trainings on TB bacteriology & EQA held for 55 lab technicians (M-27, F-28) Support supervision visits made to all the regions 20 KAPTLTD facilities supported to develop and implement IPC workplans 23 out of 61 private laboratories in Nairobi were provided technical support
	1.2.3	Improve TB case finding (early & complete TB case finding) and treatment outcomes for all forms of TB among vulnerable groups (PLHIV, diabetes & slum dwellers)	KNCV	39,111	12%	Sept	2012	26 sputum collection sites established 246 sputum specimens collected (22 sputum positive TB diagnosed)
	1.2.4	Enhance national TB surveillance system by promoting implementation of public health responsibilities by all providers managing TB	KNCV	41,094	39%	Sept	2012	All the 215 KAPTLTD supported facilities provided with reporting and M&E tools
					29%			

2. Laboratories								
Outcome	Activity #	Activity	Activity	Approved Budget	Cumulative Completion	Planned Completion Month	Year	Cumulative Progress and Deliverables up-to-date
2.1 Ensured capacity, availability and quality of laboratory testing to support the diagnosis and monitoring of TB patients	2.1.1	Support EQA	MSH	100,096	0%	Sept	2012	Activity supported through GF funds until end of April 2012.
	2.1.2	Support Specimen referral system	MSH	168,854	46%	Sept	2012	A total of 4,154 samples received in CRL (October 2011-786, November 2011-901, December 2011-675, January 2012 - 618, February 2012- 540, March 2012-634)
Outcome	Activity #	Activity	Activity	Approved Budget	Cumulative Completion	Planned Completion Month	Year	Cumulative Progress and Deliverables up-to-date
2.3 Ensured optimal use of new approaches for laboratory confirmation of TB and incorporation of these approaches in national strategic laboratory plans	2.3.1	Support utilization of new technologies for rapid test	KNCV	46,800	50%	Sept	2012	3 laboratories in Coast supported to use Gene Xpert machines. Follow up and support supervision visit made in March 2012. A total of 531 samples have been tested (Oct 2011 to Feb 2012) 223 cases were MTB positive 10 cases were Rifampicin resistant (all were retreatment cases) 39 were new TB cases Annual calibration of Gene Xpert planned for September 2012
					32%			

3. Infection Control								
Outcome	Activity #	Activity	Activity	Approved Budget	Cumulative Completion	Planned Completion Month	Year	Cumulative Progress and Deliverables up-to-date
3.1 Increased TB-IC Political Commitment	3.1.1	Support TB IC training material development	KNCV	8,337	30%	March	2012	Draft training materials developed and shared with stakeholders. Awaiting feedback/inputs before finalization
					30%			

4. PMDT									
Outcome	Activity #	Activity	Activity	Approved Budget	Cumulative Completion	Planned Completion Month	Year	Cumulative Progress and Deliverables up-to-date	
4.1 Improved treatment success of MDR TB	4.1.1	MDR TB patient support	KNCV	240,706	0%	Sept	2012	Support for this activity starts in May 2012	
	4.1.2	GLC/PMDT TA	KNCV	12,649	0%	Sept	2012	Planned for next quarter	
	4.1.3	MDR TB contact tracing	KNCV	24,671	25%	Sept	2012	17 contacts of MDR TB patients traced and screened for TB 21 MDR TB cases confirmed Jan to March 2012 (estimation for family size of 4 gives 84 contacts for)	
	4.1.4	PMDT Guideline revision, training material and SOP development	KNCV	8,824	0%	Sept	2012	Activity planned for May 2012	
					6%				

5. TB/HIV									
Outcome	Activity #	Activity	Activity	Approved Budget	Cumulative Completion	Planned Completion Month	Year	Cumulative Progress and Deliverables up-to-date	
5.2 Improved diagnosis of TB/HIV co-infection	5.1.1	Printing of TBHIV SOPS and IPT tools	KNCV	10,588	0%	June	2012	Activity planned for May 2012	
					0%				

6. Health Systems Strengthening								
Outcome	Activity #	Activity	Activity	Approved Budget	Cumulative Completion	Planned Completion Month	Year	Cumulative Progress and Deliverables up-to-date
6.1 TB control is embedded as a priority within the national health strategies and plans, with matching domestic financing and supported by the engagement of partners	6.1.1	Hold regular coordination meeting including CU staff meetings and partners meeting	KNCV	9,059	50%	Sept	2012	Partners meeting held AT TB CARE I Office. It was attended by the following partners: DLTLD, ministry of finance, WHO, JICA, CDC, MSH, FHI 360, KNCV, KAPTLD, KANCO. This was to prepare for the National workshop on "Sustainable Financing of TB Programme in Kenya". The meeting discussed approaches to the agenda of the national workshop. Monthly Management meetings between DLTLD and TB CARE I held
	6.1.2	Hold joint SS and support Adhoc visits to the field	KNCV	7,588	37%	Sept	2012	Two joint supervision visits supported. Gene Xpert implementation follow up visit in the Coast region and the Support supervision on the use of PDAs in Rift Valley North region.
	6.1.3	Support ISO certification process and implementation of DLTLD	KNCV	16,976	32%	March	2012	ISO certification process on going. Stage I and II audit to be conducted by Kenya Bureau of Standards in May 2012. Payment for audit is done.
	6.1.4	Resource management	KNCV	9,471	0%	Sept	2012	Activity planned for next quarter
	6.1.5	Introduce New technology for Operational management of TB program	KNCV	500,000	30%	Sept		Quotations advertised, analysed Safricom company awarded. The budget submitted to USAID Washington for consideration and approval.

	6.1.6	National workshop on sustainable financing	KNCV	6,982	🟡	20%	March	2012	<p>Preparations for the workshop ongoing. Consultative meeting held with key TB Control Partners in Kenya.</p> <p>Concept paper developed and discussed in the consultative meeting.</p> <p>Meeting postponed to provide more time for planning</p>
--	--------------	--	------	-------	---	-----	-------	------	---

Outcome	Activity #	Activity	Activity	Approved Budget	Cumulative Completion	Month	Year	Cumulative Progress and Deliverables up-to-date
6.2 TB control components (drug supply and management, laboratories, community care, HRD and M&E) form an integral part of national plans, strategies and service delivery	6.2.1	TB program Supervision at all level	KNCV	1,123,328	27%	Sept	2012	Monthly districts supervision coverage: October 2011 - 76%, November 2011 - 74%, December 2011 - 64%, January 2012 - 81%
	6.2.2	Printing and distribution of data capture tools	KNCV	33,529	0%	June	2012	Activity not done
	6.2.3	Facilitate communication to coordinate implementation of the annual work plan of DLTD	KNCV	225,824	32%	Sept	2012	DLTDL staff provided with airtime and internet services
					25%			

7. M&E, OR and Surveillance

Outcome	Activity #	Activity	Activity	Approved Budget	Cumulative Completion	Planned Completion Month	Year	Cumulative Progress and Deliverables up-to-date
7.1 Strengthened TB surveillance	7.1.1	TA on web based surveillance	KNCV	21,181	0%	June	2012	Activity planned for next quarter. TOR for this mission has been developed and agreed upon with DLTDL.
7.2 Improved capacity of NTPs to analyze and use quality data for the management of the TB program	7.2.1	Conduct Review Meetings at all level	KNCV	541,399	25%	Sept	2012	One annual meeting for provincial TB coordinators held March 2012 12 quarterly meeting for the 12 regions held in February & March 2012. TB CARE I supported 3 quarterly meetings out of the 12 meetings due to delay in budget approval.
	7.2.2	TA for mortality study	KNCV	25,628	0%	Sept	2012	Activity planned for fourth quarter
					8%			

8. Drug supply and management

Outcome	Activity #	Activity	Activity	Approved Budget	Cumulative Completion	Planned Completion Month	Year	Cumulative Progress and Deliverables up-to-date
8.1 Ensured nationwide systems for a sustainable supply of drugs	8.1.1	Improved commodity clearance from ports and support drug distribution	KNCV	14,118	36%	June	2012	Support provided to distribute drugs to three regions during reporting period: Rift Valley North, Nyanza South & Western Support provided for Clearance of drugs twice during the reporting quarter.
					36%			

Quarterly MDR-TB Report

Country	Kenya
---------	-------

Period	January-March 2012
--------	--------------------

MDR TB cases diagnosed and put on treatment in country

Quarter	Number of MDR cases diagnosed	Number of MDR cases put on treatment
Jan-Dec 2010	112	59
Jan-Dec 2011	130	130
Oct-Dec 2011		
Total 2011	130	130
Jan-Mar 2012	21	21

There is no diagnosed MDR patient not on treatment to the knowledge of the NTP.

Quarterly GeneXpert Report

Country	Kenya
---------	-------

Period	January-March 2012
--------	--------------------

Table 1: GeneXpert instruments and cartridges procured or planned by quarter

	Procured			# still planned for procurement in APA 2	Month, Year procurement planned (i.e. April 2012)
	Jan-Sep 2011	Oct-Dec 2011	Jan-Dec 2011		
# GeneXpert Instruments	3	0	3	0	0
# Cartridges	1000	0	1000	1450	Jul-12

Table 2: Cumulative List of GeneXpert Instruments Procured to Date or Planned in the Next Quarter

Already procured or still planned? (i.e. Write "Procured" or "Planned")	Instrument	# of Modules (1, 2, 4, or 16)	Location(s) (facility name & city/ province or TBD)	USG Funding Source (e.g., PEPFAR COP FYxx, USAID) ¹	Partner/ Implementing Organization; Additional Comments
Procured	1	4	Coast General Hospital	PEPFAR COP FY10	TB CARE I (KNCV and MSH)
Procured	2	4	Likoni District Hospital	PEPFAR COP FY10	TB CARE I (KNCV and MSH)
Procured	3	4	Port Reitz District Hospital	PEPFAR COP FY10	TB CARE I (KNCV and MSH)
	4				
	5				
	6				
	7				
	8				

¹ Differentiating between PEPFAR and USAID-funded is important. If it is PEPFAR funded, specify the fiscal year (i.e. FY2011). Add rows if there are more than 8 instruments in total.

Table 3: Cumulative Xpert MTB/RIF Cartridges Procured to Date or Planned for Next Quarter

Already procured or still planned? (i.e. Write "Procured" or "Planned")	Order #	# of Cartridges*	Location(s) (facility name and city/ province or TBD)	USG Funding Source (e.g., PEPFAR COP FYxx, USAID) ¹	Comments
Procured	1	1000	To be distributed to the 3 facilities according to consumption	PEPFAR COP FY10	1000 cartridges have been received and the balance (2000 cartridges) were to be procured under APA 1 but the APA 1 budget has been closed.
Planned	2	1450	To be distributed to the 3 facilities according to consumption	PEPFAR COP FY11	To be procured by end of September 2012

*There are 10 cartridges per kit, but we need the total # of **cartridges** (not kits)
Add an additional row for every procurement order of cartridges

Any additional information/clarifications to the above (optional)

Under APA 1, the plan was to procure 3000 cartridges. Out of these, 1000 cartridges have been procured and received . 2000 cartridges were to be procured in March 2012. However, these 2000 cartridges will not be procured since the APA 1 budget has been

Please provide a brief description of any significant problems encountered in use of the GeneXpert machine(s) and Xpert MTB/RIF cartridges

No significant problem

Please describe technical assistance or evaluation of implementation activities performed and planned.

There is monthly monitoring of implementation and analysis will be done once enough data is collected



Quarterly Photos (as well as tables, charts and other relevant materials)



GeneXpert Machine installed at Coast Provincial General Hospital Laboratory for public use





TB CARE I Country Director hands over a LED microscope to the Director of Disease control & Prevention (under the Ministry of Public Health & San









itation) as the Head of DLTLD looks on.

Inventory List of Equipment - TB CARE I



USAID
FROM THE AMERICAN PEOPLE

TB CARE I

Organization:	TB CARE I
Country:	Kenya
Reporting period:	January-March 2012
Year:	APA 2

Description (1)	ID numbers (2)	Acquisition date (3)	Acquisition cost (4)	V.A.T (5)	Location (6)	Condition (7)	Disposition date (8)	Title held by (9)	Insurance Policy #
HP Laptop HP pro book	CNF1142NCV	40695	74,100.00	NIL	KNCV/TBCARE Office	Good		Sentayehu	
HP Laptop HP pro book	CNF1142ND8	40695	74,100.00	NIL	KNCV/TBCARE Office	Good		Pamela Liyala	
HP Laptop HP pro book	CNF1142NBQ	40695	74,100.00	NIL	KNCV/TBCARE Office	Good		Anne Mwindi	
Xerox Photocopier	KRK1JC9603997A	2010	170,000.00	NIL	KNCV/TBCARE Office	Good		KNCV Office	
HP 2050 Printer	CNCJK92664	2010	40,000.00	NIL	KNCV/TBCARE Office	Good		On Alice Desk	
HP 2050 Printer	CNCJH3932	2010	56,000.00	NIL	KNCV/TBCARE Office	Good		On Joseph's office	
HP 2050 Printer	CNCJH39640	2010	35,000.00	NIL	KNCV/TBCARE Office	Good		On Siano's desk	
PABX Machine KX-TEMP	OEBCP017261	40632	58,300.00	NIL	KNCV/TBCARE Office	Good		KNCV/TBCARE Office	
CDMA Box	RR6RSA1080400404	40632	12,000.00	NIL	KNCV/TBCARE Office	Good		KNCV/TBCARE Office	
GSM router	TAS6RD10A2100352	40632	13,500.00	NIL	KNCV/TBCARE Office	Good		KNCV/TBCARE Office	
GSM router	TAS6RD10A2100249	40632	13,500.00	NIL	KNCV/TBCARE Office	Good		KNCV/TBCARE Office	
HP Scanner G4010	UN03CA6132	40695	16,500.00	NIL	KNCV/TBCARE Office	Good		TBCARE Office(Alice)	
HP Scanner G4011	CN03CA6032	40725	16,501.00	NIL	KNCV/TBCARE Office	Good		TBCARE Office(joseph)	
Linksys Wireless Access	MD 930J826938	40575	5,700.00	NIL	KNCV/TBCARE Office	Good		KNCV/TBCARE Office	
Linksys Wireless Access	MD 930J826936	40575	5,700.00	NIL	KNCV/TBCARE Office	Good		KNCV/TBCARE Office	
Cisco Router 881 Series	TAS6RDIOA2100352	40603	13,500.00	2,160.00	KNCV/TBCARE Office	Good		KNCV/TBCARE Office	
Cisco Router 881 Series	TASRDIOA2100249	40603	13,500.00	2,160.00	KNCV/TBCARE Office	Good		KNCV/TBCARE Office	
HP laser jet printer P40	CNFY880851	40695	132,000.00	NIL	KNCV/TBCARE Office	Good		KNCV/TBCARE Office	
24 point switch	F3UH4AA00791	40544	4,900.00	784.00	KNCV/TBCARE Office	Good		KNCV/TBCARE Office	
Server rack	15632		88,848.75	14,215.80	KNCV/TBCARE Office	Good		KNCV/TBCARE Office	

Shredder	101026VB0131981	40695	23,200.00	NIL	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Felowees binding mach	5005622001	40756	35,800.00	NIL	DLTLD	Good		DLTLD
Modem	351817041107279	Feb-11	1,723.28	827.17	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Modem	351817041125669	Feb-11	1,723.28		KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Modem	351817041120942	Feb-11	1,723.28		KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Telephone extension	OLCKC421773	30th mar 2011	2,200.00	352.00	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Telephone extension	OLCKC421732	30th mar 2011	2,200.00	352.00	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Telephone extension	OLCKC1740	30th mar 2011	2,200.00	352.00	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Telephone extension	OLBKC419134	30th mar 2011	2,200.00	352.00	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Telephone extension	OLBKC419125	30th mar 2011	2,200.00	352.00	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Telephone extension	OLBKC419112	30th mar 2011	2,200.00	352.00	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Telephone extension	OLBKC419272	30th mar 2011	2,200.00	352.00	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Telephone extension	OLBKC419267	30th mar 2011	2,200.00	352.00	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Telephone extension	OLBKC419259	30th mar 2011	2,200.00	352.00	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Telephone extension	OLBKC419282	30th mar 2011	2,200.00	352.00	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Telephone extension	OLBKC419290	30th mar 2011	2,200.00	352.00	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Telephone extension	OLBKC419270	30th mar 2011	2,200.00	352.00	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Telephone extension	OLBKC419235	30th mar 2011	2,200.00	352.00	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Telephone extension	OLBKC417535	30th mar 2011	2,200.00	352.00	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Telephone extension	OLBKC417555	30th mar 2011	2,200.00	352.00	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Telephone extension	OLBKC417534	30th mar 2011	2,200.00	352.00	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Telephone operator set	OLACD364078	30th mar 2011	7,000.00	1,120.00	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Extension cables	9921AZOIP5928	Mar-11	1,625.00	2,150.34	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Extension cables	9921AZOIP5928	Mar-11	1,625.00		KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Extension cables	9921AZOIP5928	Mar-11	1,625.00		KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Extension cables	9921AZOIP5928	Mar-11	1,625.00		KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Extension cables	9921AZOIP5928	Mar-11	1,625.00		KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Extension cables	9921AZOIP5928	Mar-11	1,625.00		KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Extension cables	9921AZOIP5928	Mar-11	1,625.00		KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Extension cables	9921AZOIP5928	Mar-11	1,625.00		KNCV/TBCARE Office	Good		KNCV/TBCARE Office
surge protector		Mar-11	1,295.00		KNCV/TBCARE Office	Good		KNCV/TBCARE Office
surge protector		Mar-11	1,295.00		KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Typewriter	DOK357393	Sep-11	55,600.00	NIL	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Microwave oven- Ramt	02994/10120832	2011	5,700.00	912.00	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Water dispenser - Ramt	02950/10540	2011	14,500.00	2,320.00	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
4 way working station	N/A	Mar-11	81,270.00	13,003.20	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
4 way working station	N/A	Mar-11	81,270.00	13,003.20	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
4 way working station	N/A	Mar-11	81,270.00	13,003.20	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
4 way working station	N/A	Mar-11	81,270.00	13,003.20	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
2 way working station	N/A	Mar-11	37,135.00	5,941.60	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
2 way working station	N/A	Mar-11	37,135.00	5,941.60	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Medium back fabric cha	N/A	Mar-11	6,807.50	9,525.60	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Medium back fabric cha	N/A	Mar-11	6,807.50		KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Medium back fabric cha	N/A	Mar-11	6,807.50		KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Medium back fabric cha	N/A	Mar-11	6,807.50		KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Medium back fabric cha	N/A	Mar-11	6,807.50		KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Medium back fabric cha	N/A	Mar-11	6,807.50		KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Medium back fabric cha	N/A	Mar-11	6,807.50		KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Medium back fabric cha	N/A	Mar-11	6,807.50		KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Medium back fabric cha	N/A	Mar-11	6,807.50		KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Medium back fabric cha	N/A	Mar-11	6,807.50		KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Medium back fabric cha	N/A	Mar-11	6,807.50		KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Medium back fabric cha	N/A	Mar-11	6,807.50		KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Medium back fabric cha	N/A	Mar-11	6,807.50		KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Medium back fabric cha	N/A	Mar-11	6,807.50		KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Medium back fabric cha	N/A	Mar-11	6,807.50	KNCV/TBCARE Office	Good		KNCV/TBCARE Office	
Board room table	N/A	Mar-11	58,450.00	9,352.00	KNCV/TBCARE Office	Good		KNCV/TBCARE Office
Filing cabinets	N/A	Mar-11	8,277.50	1,324.40	KNCV/TBCARE Office	Good		KNCV/TBCARE Office

Conference table	N/A	Mar-11	7,175.00	1,148.00	KNCV/TBCARE Office	Good	KNCV/TBCARE Office
Conference table	N/A	Mar-11	7,175.00	1,148.00	KNCV/TBCARE Office	Good	KNCV/TBCARE Office
CPU trolley	N/A	Mar-11	2,275.00	364.00	KNCV/TBCARE Office	Good	KNCV/TBCARE Office
CPU trolley	N/A	Mar-11	2,275.00	364.00	KNCV/TBCARE Office	Good	KNCV/TBCARE Office
CPU trolley	N/A	Mar-11	2,275.00	364.00	KNCV/TBCARE Office	Good	KNCV/TBCARE Office
Lagenda stackable chair	N/A	Mar-11	4,970.00	9,525.60	KNCV/TBCARE Office	Good	KNCV/TBCARE Office
Lagenda stackable chair	N/A	Mar-11	4,970.00		KNCV/TBCARE Office	Good	KNCV/TBCARE Office
Lagenda stackable chair	N/A	Mar-11	4,970.00		KNCV/TBCARE Office	Good	KNCV/TBCARE Office
Lagenda stackable chair	N/A	Mar-11	4,970.00		KNCV/TBCARE Office	Good	KNCV/TBCARE Office
Lagenda stackable chair	N/A	Mar-11	4,970.00		KNCV/TBCARE Office	Good	KNCV/TBCARE Office
Lagenda stackable chair	N/A	Mar-11	4,970.00		KNCV/TBCARE Office	Good	KNCV/TBCARE Office
Lagenda stackable chair	N/A	Mar-11	4,970.00		KNCV/TBCARE Office	Good	KNCV/TBCARE Office
Lagenda stackable chair	N/A	Mar-11	4,970.00		KNCV/TBCARE Office	Good	KNCV/TBCARE Office
Lagenda stackable chair	N/A	Mar-11	4,970.00		KNCV/TBCARE Office	Good	KNCV/TBCARE Office
Lagenda stackable chair	N/A	Mar-11	4,970.00		KNCV/TBCARE Office	Good	KNCV/TBCARE Office
Lagenda stackable chair	N/A	Mar-11	4,970.00		KNCV/TBCARE Office	Good	KNCV/TBCARE Office
Lagenda stackable chair	N/A	Mar-11	4,970.00		KNCV/TBCARE Office	Good	KNCV/TBCARE Office
Lagenda stackable chair	N/A	Mar-11	4,970.00		KNCV/TBCARE Office	Good	KNCV/TBCARE Office
Lagenda stackable chair	N/A	Mar-11	4,970.00		KNCV/TBCARE Office	Good	KNCV/TBCARE Office
High cabinet shelves	N/A	Mar-11	19,200.00	3,072.00	KNCV/TBCARE Office	Good	KNCV/TBCARE Office
High cabinet shelves	N/A	Apr-11	19,200.00	3,072.00	KNCV/TBCARE Office	Good	KNCV/TBCARE Office
High cabinet shelves	N/A	May-11	19,200.00	3,072.00	KNCV/TBCARE Office	Good	KNCV/TBCARE Office
Waiting seat	N/A	Mar-11	22,050.00	3,528.00	KNCV/TBCARE Office	Good	KNCV/TBCARE Office
Executive office desk	N/A	Sep-11	165,000.00	NIL	DLTD	Good	DLTD
Book case with glass doors	N/A	Sep-11	59,250.00	NIL	DLTD	Good	DLTD
coffee stool with magazine rack	N/A	Sep-11	16,000.00	NIL	DLTD	Good	DLTD
Executive round meeting table	N/A	Sep-11	39,150.00	NIL	DLTD	Good	DLTD
3 seater sofa	N/A	Sep-11	48,938.00	NIL	DLTD	Good	DLTD
Executive secretarial desk	N/A	Sep-11	56,250.00	NIL	DLTD	Good	DLTD
Executive glass door bookcase	N/A	Sep-11	30,750.00	NIL	DLTD	Good	DLTD
Medium back mesh chair	N/A	Sep-11	44,800.00	NIL	DLTD	Good	DLTD
Medium back meeting chair	N/A	Sep-11	57,600.00	NIL	DLTD	Good	DLTD
Single coat hanger	N/A	Sep-11	5,000.00	NIL	DLTD	Good	DLTD
Gene Expert Machine	707421			NIL	port reitz district hospital	Good	DLTD
DELL Desktop	43024411945			NIL	port reitz district hospital	Good	DLTD
UPS	5508023R-1120019			NIL	port reitz district hospital	Good	DLTD
barcode reader	1106900504348			NIL	coast provincial general hospital	Good	DLTD
Gene Expert Machine	707443			NIL	Likoni district hospital	Good	DLTD
DELL Desktop	7590351529			NIL	Likoni district hospital	Good	DLTD
UPS	5508023R-1110014			NIL	Likoni district hospital	Good	DLTD
barcode reader	110000507026			NIL	Likoni district hospital	Good	DLTD
Gene Expert Machine	707436			NIL	coast provincial general hospital	Good	DLTD
DELL Desktop	7593429529			NIL	coast provincial general hospital	Good	DLTD
UPS	5508023R-1120024			NIL	coast provincial general hospital	Good	DLTD
barcode reader	110000507262			NIL	port reitz district hospital	Good	DLTD
HP Desktop 500B	TRF12035H6	09/07/2011	70,000.00	NIL	DLTD	Good	DLTD
HP Desktop 500B	TRF12035MB	09/07/2011	70,000.00	NIL	DLTD	Good	DLTD
HP Desktop 500B	TRF120358P	09/07/2011	70,000.00	NIL	DLTD	Good	DLTD
HP Desktop 500B	TRF12035CL	09/07/2011	70,000.00	NIL	DLTD	Good	DLTD
HP Desktop 500B	TRF12035FT	09/07/2011	70,000.00	NIL	DLTD	Good	DLTD
HP Desktop 500B	TRF12035LN	09/07/2011	70,000.00	NIL	DLTD	Good	DLTD
HP Desktop 500B	TRF12035B2	09/07/2011	70,000.00	NIL	DLTD	Good	DLTD
HP Desktop 500B	TRF12035HL	09/07/2011	70,000.00	NIL	DLTD	Good	DLTD
HP Desktop 500B	TRF12035G4	09/07/2011	70,000.00	NIL	DLTD	Good	DLTD
HP Desktop 500B	TRF12035HF	09/07/2011	70,000.00	NIL	DLTD	Good	DLTD
HP Desktop 500B	TRF12035JS	09/07/2011	70,000.00	NIL	DLTD	Good	DLTD
HP Desktop 500B	TRF12035BM	09/07/2011	70,000.00	NIL	DLTD	Good	DLTD
HP Desktop 500B	TRF12035HP	09/07/2011	70,000.00	NIL	DLTD	Good	DLTD

HP Desktop 500B	TRF12035D0	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035HR	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035K0	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035FR	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035D6	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035G1	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035H3	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035G3	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035C1	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035GF	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF120358M	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035CG	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035KK	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035LV	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035B3	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035JK	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF120358N	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035GZ	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035HU	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035H4	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035GV	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035GU	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035C3	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035K9	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035GJ	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035B8	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035FY	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF120358K	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035DW	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035CF	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035F5	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035JJ	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035KQ	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035BY	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035BX	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035C7	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035G6	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF120357Z	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035DL	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035DD	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035C4	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035GH	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035LP	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035DB	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF120359K	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF120359T	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
HP Desktop 500B	TRF12035D9	09/07/2011	70,000.00	NIL	DLTLD	Good		DLTLD	
Acer LCD Projector	EYJBU01039112021E259	09/07/2011	50,000.00	NIL	DLTLD	Good		DLTLD	
Acer LCD Projector	EYJBU010391120220459	09/07/2011	50,000.00	NIL	DLTLD	Good		DLTLD	
Acer LCD Projector	EYJBU01039112021D259	09/07/2011	50,000.00	NIL	KNCV/TBCARE	Good		KNCV/TBCARE	
Acer LCD Projector	EYJBU01039112021FB59	09/07/2011	50,000.00	NIL	DLTLD	Good		DLTLD	
Acer LCD Projector	EYJBU01039112021DC59	09/07/2011	50,000.00	NIL	DLTLD	Good		DLTLD	
Acer LCD Projector	EYJBU01039112021F159	09/07/2011	50,000.00	NIL	DLTLD	Good		DLTLD	
Acer LCD Projector	EYJBU01039112021CE59	09/07/2011	50,000.00	NIL	DLTLD	Good		DLTLD	
Scanner HP G4010	CNOC8A60PB	10/07/2011	13,500.00	NIL	DLTLD	Good		DLTLD	
Scanner HP G4010	CNOC8A611C	11/07/2011	13,500.00	NIL	DLTLD	Good		DLTLD	
Xerox 5745 photocopier		Sep-11	700,000.00	NIL	DLTLD	Good		DLTLD	

